Literature DB >> 9242464

Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor.

L L Thomsen1, J M Scott, P Topley, R G Knowles, A J Keerie, A J Frend.   

Abstract

We have investigated the effect of N-(3-(aminomethyl)benzyl)acetamidine (1400W), a novel and highly selective inhibitor for inducible NOS (iNOS), on in vivo growth of solid tumors expressing iNOS. For the EMT6 murine mammary adenocarcinoma, in which iNOS is expressed in the tumor cells, continuous infusion of 1400W for 6 days at 10 or 12 mg/kg(-1)/h(-1) resulted in significant reduction in tumor weight (357 +/- 46 and 466 +/- 70 mg, respectively) compared with that of controls [726 +/- 65 (P < 0.001) and 796 +/- 88 mg (P < 0.02), respectively]. Reduced growth was also observed for a human tumor xenograft (colon adenocarcinoma DLD-1) genetically engineered to express iNOS constitutively and treated for 13 days with 6 mg/kg(-1)/h(-1) 1400W compared with controls (tumor weights 340 +/- 50 and 580 +/- 90 mg, respectively; P < 0.03). Growth of the parental DLD-1 clone was not altered with this treatment compared with that of controls (tumor weights 170 +/- 10 and 240 +/- 50 mg, respectively). Inhibition of iNOS in vivo was confirmed by decreases in plasma nitrite + nitrate concentrations in treated animals compared with that of controls (63-83% decreases for all experiments) and was supported by plasma and tumor concentrations of 1400W that were equivalent and 2.6-4.9 times higher than the EC50 previously reported for iNOS in a tissue assay. For the murine colon adenocarcinoma Colon 38, in which intratumoral macrophages are the predominant source of iNOS and which had high intratumoral arginine concentrations, 1400W treatment had no effect on growth or plasma nitrate + nitrate. Future studies with more potent selective iNOS inhibitors and a wider range of tumors may determine whether iNOS inhibitors could represent a novel approach to the treatment of cancer. These studies confirm that nitric oxide production in tumors plays a role in promoting their growth, rather than a role as a host defense mechanism in inhibiting growth.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9242464

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Angiogenesis in cancer: the role of endothelin-1.

Authors:  P A Brennan; G A Zaki
Journal:  Ann R Coll Surg Engl       Date:  2000-09       Impact factor: 1.891

2.  NOS-2 Inhibition in Phosgene-Induced Acute Lung Injury.

Authors:  Piotr T Filipczak; Albert P Senft; JeanClare Seagrave; Waylon Weber; Philip J Kuehl; Laura E Fredenburgh; Jacob D McDonald; Rebecca M Baron
Journal:  Toxicol Sci       Date:  2015-04-13       Impact factor: 4.849

3.  Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2.

Authors:  Christine E Eyler; Qiulian Wu; Kenneth Yan; Jennifer M MacSwords; Devin Chandler-Militello; Katherine L Misuraca; Justin D Lathia; Michael T Forrester; Jeongwu Lee; Jonathan S Stamler; Steven A Goldman; Markus Bredel; Roger E McLendon; Andrew E Sloan; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cell       Date:  2011-07-08       Impact factor: 41.582

Review 4.  Nitric oxide and angiogenesis.

Authors:  M Ziche; L Morbidelli
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

5.  Expression of inducible nitric oxide synthase in keratocystic odontogenic tumour and variants of ameloblastoma - a comparative study.

Authors:  Diana H; Maya R; Sekar B; Murali S; Ramesh K
Journal:  J Clin Diagn Res       Date:  2014-11-20

6.  Protein nitration in cutaneous inflammation in the rat: essential role of inducible nitric oxide synthase and polymorphonuclear leukocytes.

Authors:  S A B Greenacre; F A C Rocha; A Rawlingson; S Meinerikandathevan; R N Poston; E Ruiz; B Halliwell; S D Brain
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

7.  Chemoprevention of Colon Cancer by iNOS-Selective Inhibitors.

Authors:  Naveena B Janakiram; Chinthalapally V Rao
Journal:  For Immunopathol Dis Therap       Date:  2012-01-01

Review 8.  iNOS: a potential therapeutic target for malignant glioma.

Authors:  A Jahani-Asl; A Bonni
Journal:  Curr Mol Med       Date:  2013-09       Impact factor: 2.222

9.  17beta-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response.

Authors:  E C Chinje; K J Williams; B A Telfer; P J Wood; A J van der Kogel; I J Stratford
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

10.  Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers.

Authors:  L Morbidelli; S Donnini; S Filippi; L Messori; F Piccioli; P Orioli; G Sava; M Ziche
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.